The startup develops immunomodulatory therapeutics that target autoimmunity and cancer by utilizing proprietary transcription data analysis to identify key immune system compartments. This approach enables healthcare professionals to tailor treatment plans for more effective patient outcomes.

Circle Pharma designs and develops bioavailable macrocyclic peptide therapeutics targeting intracellular protein-protein interactions, particularly those involved in cancer. Their computational structure-based design approach combines physics-based conformational modeling and innovative chemistry to create permeable macrocyclic peptide drug candidates.

Mediar is developing therapeutics that target fibrotic mediators to neutralize myofibroblasts, the key cells responsible for collagen deposition and organ scarring in fibrosis. This approach aims to slow disease progression and promote tissue regeneration in patients suffering from fibrotic diseases.

Morphic Therapeutic develops oral integrin therapies that target chronic diseases by modulating immune responses through specific integrin interactions. This approach aims to improve patient outcomes by providing a more effective and convenient treatment option compared to traditional intravenous therapies.

The startup develops controllable cell and gene therapies that utilize pharmacologic operating systems to regulate protein activity in cells. This technology enables physicians to enhance the efficacy of adoptive immunotherapy for cancer patients by using safe, orally active drugs to exert precise control over cell functions.

Pykus Therapeutics is developing PYK-2101, a biodegradable retinal sealant that eliminates the need for facedown positioning and reduces blurred vision during recovery from retinal surgery. This technology addresses the significant post-operative burdens faced by patients, enhancing their overall recovery experience.

Skyhawk Therapeutics develops small molecule therapeutics that modify RNA expression to target diseases such as Huntington's Disease, with its lead candidate, SKY-0515, demonstrating a 72% reduction in HTT mRNA during clinical trials. The company's proprietary SKYSTAR® platform accelerates the creation of RNA-targeting drugs across neurology, oncology, and fibrotic diseases, addressing significant unmet medical needs.